Please assess the completion status of the following clinical trial:

Trial Title: Corticosteroid Injection Combined With Cataract Surgery in Diabetic Eyes.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ● A history of diabetes mellitus DM type II that is well-confirmed by an endocrinologist.~  * Senile cataract that is causing visual disturbance as demonstrated by clinical examination.~ * CDVA of no more than 20/ 40, finger count and hand movement vision are included. Too.~ * Diabetic retinopathy that falls in one of the following categories according to the International Clinical Diabetic Retinopathy Disease Severity Scale: No DR- mild NPDR- moderate NPDR.~ * A healthy-looking central macula, or Clinically Significant Macular Edema (CSME), or edema that is apparent on Fundus Fluorescent Angiography (FFA) or OCT, as well as a treatment-resistant diabetic macular edema in the past 24 months or microaneurysms at foveal avascular zone (FAZ) borders not amenable to laser therapy.~ * Both sexes, Age 18 years or older.~ * One eye per patient will be included.~ * The surgery will be performed by the same surgeon and the samIOL design will be used.~Exclusion Criteria:~* • A history of diabetes mellitus DM type I that is well-confirmed by an endocrinologist or no history of DM.~  * CDVA that is better than 20/40.~ * functionally monocular patient as a result of moderate to severe visual impairment in the contralateral eye, as per the definition of the International Statistical Classification of Diseases and Related Health Problems, 10th revision (6).~ * The presence of pathologies other than diabetic retinopathy and cataract that may justify visual acuity decline (e.g. corneal disease, age related macular degeneration, macular hole, etc...).~ * patients will be excluded if they had an increased risk for developing CME in the study eye because of a complication during the current or previous intraocular surgery, intraocular inflammation or uveitis, retinal vein occlusion, or macular pathology that might influence visual function, other than diabetic macular edema.~ * Patients with pseudoexfoliation syndrome, Fuchs endothelial dystrophy, or post-traumatic cataract in the study eye.~ * Diabetic retinopathy that falls in one of the following categories according to the International Clinical Diabetic Retinopathy Disease Severity Scale: severe NPDR, proliferative DR, or vitreous hemorrhage requiring pan-retinal photocoagulation or vitrectomy.~ * Patients who used topical NSAIDs, topical or systemic corticosteroids before surgery.~ * patients who received an intravitreal injection with any kind of anti-VEGF in the study eye in the previous 6 weeks, or an intraocular or periocular corticosteroid injection in the previous 3 months.~ * patients who received PRP during the past 3 months.~ * Contraindications for any of the investigated drugs, particularly patients with glaucoma, IOP of 21mm Hg or higher, previous steroid-induced IOP elevation, or ganglion cell/ RNFL complex injury on OCT image.~ * History of steroid hypersensitivity.~ * Patients who are taking steroids PO with a total dosage of more than 5 mg/ day.~ * Pregnant and breastfeeding ladies.~ * Previous surgery on the study eye.~ * systemic bleeding in the previous 3 months, major systemic surgery in the previous 3 months, or a recent or recurrent cerebrovascular accident, myocardial infarction, or thromboembolic event.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- IVTA group (Type: EXPERIMENTAL): Patients will receive an intravitreal injection of 4 mg/0.1 mL preservative-free triamcinolone acetonide at the end of surgery.
- No injection group (Type: NO_INTERVENTION): Patients will receive no additional treatment to the standard phacoemulsification surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).